-

STAAR Surgical to Participate in BTIG Ophthalmology Day

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors and a fireside chat at the 4th Annual BTIG Ophthalmology Day.

Event: 4th Annual BTIG Ophthalmology Day
Management Attendee: Thomas G. Frinzi, Chair of the Board, President and CEO
Date: Monday, December 2, 2024
Fireside Chat: 4:00 p.m. ET / 1:00 p.m. PT
Location: Attendance by invitation only from BTIG, the sponsoring brokerage firm.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

Contacts

Investors & Media
Brian Moore
Vice President, Investor Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com

STAAR Surgical Company

NASDAQ:STAA

Release Versions

Contacts

Investors & Media
Brian Moore
Vice President, Investor Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com

Social Media Profiles
More News From STAAR Surgical Company

STAAR Surgical Reiterates Compelling, Premium Cash Value Provided by Alcon Merger

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, issued the following statement: “The merger with Alcon provides STAAR stockholders with compelling, premium cash value, including a 51% premium to the closing price of STAAR common stock on August 4, 2025 (the day prior to the agreement being announced) and a 59% premium to STAAR’s 90-day Volume Weight...

STAAR Surgical Reports Second Quarter 2025 Results

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June 27, 2025. Second Quarter 2025 Financial Overview Net sales of $44.3 million down 55% Y/Y due to planned reduction of channel inventory in China Net sales excluding China of $39.0 million up 10% Y/Y Gross margin at 74.0% vs. 79.2% year ago due to...

STAAR Surgical to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the second quarter ended June 27, 2025, on Wednesday, August 6, 2025 after the market close. The Company will also host an earnings call and webcast at 4:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 2...
Back to Newsroom